Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| [2024]S257 | Other Identifier | Medical Ethics Committee of Tongji Medical College, HUST |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including â‘ patients' treatment decision making factors and treatment experiences and â‘¡ patients' unmet needs during post-treatment surveillance.
This is a mixed-methods survey study including a 2-phased sequential-explanatory design: Phase 1, Qualitative interview will be done first to explore the treatment decision factors, treatment experiences and unmet needs during post treatment surveillance, to provide components and inform the quantitative data collection. Phase 2, quantitative survey to collect data on a larger scale and allow a statistical generation of the qualitative findings.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| experimental group | 780 patients for interview |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| interview | Other | 30 for Qualitative interview and 750 for quantitative survey |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment decision making |
| 1 day. At the time of the interview. |
| Initial treatment experiences |
| 1 day. At the time of the interview. |
| Unmet needs and gaps from diagnosis to post-treatment surveillance |
| 1 day. At the time of the interview. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
It is estimated that ~780 patients will be included in this study. For qualitative insights, previous studies have shown that a minimum of 12 respondents (Guest et al. 2006) is required to reach data saturation. A sample size of ~30 will be sufficient to gather qualitative insights and attain saturation. For quantitative survey, considering most of the variables in quantitative survey are categorical variables, we tend to use 50% in the sample size formula since it will provide us with the maximum sample size required for any question, we calculated the sample size to be ~750 with a confidence interval of 95% and margin of error 5%. The number of specific experts interviewed may be fine-tuned depending on actual implementation.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gang Chen | Contact | 086-027-83662681 | tjchengang@hust.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Gang Chen, PhD | Tongji Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ying Zhou | Hefei | Anhui | 230001 | China |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005833 | Genital Neoplasms, Female |
| D002583 | Uterine Cervical Neoplasms |
| D016889 | Endometrial Neoplasms |
| ID | Term |
|---|---|
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005831 | Genital Diseases, Female |
Not provided
Not provided
| ID | Term |
|---|---|
| D007407 | Interviews as Topic |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Shuzhong Yao | Guangzhou | Guangdong | 510080 | China |
|
| Gang Chen | Wuhan | Hubei | 430030 | China |
|
| Dongling Zou | Chongqing | 430030 | China |
|
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D014594 | Uterine Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |